›› 2020, Vol. 40 ›› Issue (2): 267-.doi: 10.3969/j.issn.1674-8115.2020.02.021

• Review • Previous Articles     Next Articles

Evolution of clinical treatment in inflammatory bowel diseasesfecal microbiota transplantation

ZHOU Cheng, SUN Peng-fei, YIN Ji-yao, WANG Yang-yang, XIAO Hai-juan   

  1. 1. The First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712000, China; 2. The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210000, China; 3. Nanjing University of Chinese Medicine Hanlin College, Taizhou 225300, China; 4. State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xian 710032, China; 5. The Fourth Department of Oncology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
  • Online:2020-02-28 Published:2020-03-20
  • Supported by:
    National Natural Science Foundation of China (81303135); General Program of China Post-doctoral Science Foundation (2017M613351); Subject Innovation Team of Shaanxi University of Chinese Medicine (2019-YL06).

PDF (PC)

437

Abstract: The etiology of inflammatory bowel disease (IBD) is complex, and the mechanism has not yet been fully clarified. It is currently believed that the progression of the disease is related to the alterations of intestinal flora. Conventional medical anti-inflammatory treatment has large side effects. In recent years, with the continuous study of intestinal flora, a new kind of therapy has been applied to the disease. Many randomized controlled trials (RCT) of fecal microbiota transplantation (FMT) have achieved good therapeutic effects on IBD, and this regimen has received extensive attention. This paper reviews the progression of FMT and its mechanisms of intestinal function regulation in the past five years. Meanwhile, the challenges and future directions in the research of FMT are also summarized.

Key words: inflammatory bowel disease (IBD), fecal microbiota transplantation (FMT), intestinal flora, immunomodulation